Showing 2701-2710 of 3223 results for "".
- Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-fda-filing-acceptance-for-xipere/2479252/Bausch Health Companies and Bausch + Lomb, along with Clearside Biomedical, announced that the FDA has accepted the resubmitted new drug application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore as
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate Nyxol Including for the Treatment of Presbyopiahttps://modernod.com/news/ocuphire-granted-two-new-us-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia/2479225/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine mesylate). Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Boo
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19https://modernod.com/news/gensight-biologics-provides-2021-operations-update-in-the-context-of-covid-19/2479212/GenSight Biologics provided an update on the impact of COVID-19 on its operations in 2021. “It has been slightly over a year since we had to adjust our operations to the COVID-19 situation and provided you with an update on our activities. Although conditions have improved in many regions,
- ReGenTree Announces Additional Results From ARISE-3 Trial Using RGN-259 for the Treatment of Dry Eyehttps://modernod.com/news/regentree-announces-additional-results-from-arise-3-using-rgn-259-for-the-treatment-of-dry-eye/2479211/ReGenTree, a U.S. joint venture company between GtreeBNT and RegeneRx, announced results of additional analysis of the phase 3 clinical trial, ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye. In A
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Nicox Partners With Laboratorios Grin to Bring Zerviate to Mexicohttps://modernod.com/news/nicox-partners-with-laboratorios-grin-to-bring-zerviate-to-mexico/2479169/Nicox SA announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% in Mexico for the treatment of ocular itching associated with allerg